Daily Media Digest October 26, 2021

Science community divided on when to lift COVID-19 public health restrictions
CBC News
“Ontario has announced its plan to ease public health restrictions by the end of March 2022, but that decision continues to be a topic of debate among the science community.”
TAGS: COVID-19, pandemic, public health, Ottawa Hospital RI, Queen’s University

Flu and COVID-19 vaccines safe to take in combination, infectious-diseases specialists say
The Globe and Mail
“Doctors say it’s safe to combine COVID-19 and influenza vaccines. The Public Health Agency of Canada says it’s important for high-risk groups to receive a flu shot because it’s possible for people to become seriously ill from a combination of COVID-19 and influenza.”
TAGS: COVID-19, public health, pandemic, influenza, flu shot, Queen’s University

Hot COVID commodity – Alumnus helps create invaluable vaccine vials
Western Alumni
“Jarosch’s work on the product, known as Corning Valor® Glass, was done as senior chemical process engineer and manager of the chemical process design group at Corning.”
TAGS: COVID-19, pandemic, vaccine, vaccine vials, Western University

Seven professors named Most Powerful Women in Canada – UM Today
UM Today – University of Manitoba
“Research at the University of Manitoba is partially supported by funding from the Government of Canada Research Support Fund.”
TAGS: innovative research, women in science, research, University of Manitoba

Helping our littlest patients breathe
Hamilton Health Sciences
“Conditions can change rapidly and unpredictably for premature or critically ill newborns in the Neonatal Intensive Care Unit so careful and detailed monitoring is needed by respiratory therapists and the NICU team.”
TAGS:  NICU, premature, respiratory therapist, Hamilton Health Sciences

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
Gilead
“Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.”
TAGS: innovative research, HIV, treatment, Gilead Sciences